2024 DEA MATE Training
Speaker: Dr. Reamer Bushardt | Pharm.D., PA-C, DFAAPA
Principal Investigator Expansion of Practitioner Education in Substance Use Disorders Program, U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).
8 -HOUR ON DEMAND, FULFILLS DEA MATE TRAINING REQUIREMENT
Provides 8 hours of AMA Category 1™️ CME
ACCME, ACPE, ANCC ACCREDITED
PHYSICIANS / PHYSICIAN ASSISTANTS/ MEDICAL PROFESSIONALS, NURSE PRACTIONERS, PHARMACISTS, NURSES
Smart Phone Ready $199
Recorded January 9-11, 2024, Expires January 9, 2027
Dr. Reamer Bushardt | Pharm.D., PA-C, DFAAPA
DFAAPA Professor, Provost and Vice President for Academic Affairs, Massachusetts General Hospital Institute for Health Professions, Mass General Brigham, Boston, MA.
PA in Primary Care.
Editor-in-Chief Emeritus, Journal of the American Academy of PAs.
Principal Investigator Expansion of Practitioner Education in Substance Use Disorders Program, U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).
Session 1
BEST PRACTICES IN PRESCRIBING OPIOIDS:
1. Describe evolving opioid prescribing and regulatory practices in the United States.
2. Discuss recently released opioid prescribing guidelines, highlighting the relevance to primary care providers.
3. Describe best practices and patient care resources for managing patients with chronic nonmalignant pain, highlighting guidance from a regulatory perspective.
CASE STUDIES AND DISCUSSION IN PRESCRIBING CONTROLLED SUBSTANCES WITH LIABILITY AUTHORITY: A REGULATORY PERSPECTIVE
4. Discuss cases involving prescribers and investigations related to opioid and controlled substance prescribing.
5. Apply best practices and guidance from state regulators to prescribe with liability authority.
IDENTIFYING AND AVOIDING DRUG INJURY: A LOOK AT OLDER ADULTS AND OPIOIDS AND OTHER CONTROLLED SUBSTANCES
6. Discuss key physiologic and common pathophysiologic changes of aging that impact drug therapy.
7. Recognize high-risk controlled substances for use in older adults and medically fragile adult patients.
8. Apply age-sensitive principles for medication dosing and management to patient scenarios.
9. Apply practical tools to screen and appropriately manage complex drug regimens, including controlled substances among older or medically fragile adults.
Session 2
ADDICTION AS A BRAIN DISEASE:
1. Examine the neurobiological basis of addiction, including how addiction affects the brain, how your brain responds to drugs and behavioral changes associated with substance use disorders. Harm Reduction :
2. Discuss the concept of harm reduction and explore its role in the treatment of opioid use disorder.
SCREENING, BRIEF INTERVENTION AND REFERRAL TO TREATMENT (SBIRT)
3. Explore SBIRT, or screening, brief intervention, and referral to treatment, as a routine part of care in all healthcare practice settings.
4. Examine how peer support and self-help groups can be used as part of treatment for SUDs.
Session 3
SUBSTANCE USE DISORDER
1. Examine evidence-based treatment approaches for substance use disorders.
2. Review strategies to fully engage patients and their families in the process, including shared decision-making and building trust.
3. Gain insights into pharmacotherapeutic treatments for SUDs, including their mechanisms of actions, risks, and benefits as well as relevant psychosocial and psychotherapeutic interventions.
4. Recognize key clinical features and functional domains that need to be assessed prior to initiating SUD treatment.
5. Discuss how the American Society of Addiction Medicine (ASAM) criteria are used by clinicians in the assessment and treatment of individuals with SUD.
6. Identify guidelines and other clinical resources that can assist clinicians formulate evidence-based treatment plans for individuals with common SUDs.
PHYSICIANS / PHYSICIAN ASSISTANTS/ MEDICAL PROFESSIONALS: Accreditation: In support of improving patient care, this activity has been planned and implemented by Continuing Education, Inc. and InPharmX dba University Learning Systems. Continuing Education, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC),to provide continuing education for the healthcare team.” Physician Designation: Continuing Education, Inc. designates this activity for 8 AMA PRA Category 1 Credits
PHARMACISTS :University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for pharmacists.
Session 1A 0741-0000-24-0001-H08-P APPLICATION
Session 2A 0741-0000-24-0003-H08-P APPLICATION
Session 3A 0741-0000-24-0005-H08-P APPLICATION
NURSE PRACTITIONERS/ NURSES: This course provides 8 contact hours (0.8 CEU) to fulfill the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Category 1 Continuing Education Hours for certification renewal. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure. American Nurses Credentialing Center (ANCC) accepts formally approved continuing education sponsored by organizations accredited or approved by the Accreditation Council for Pharmacy Education (ACPE). California Board of Registered Nursing Provider: CEP11409.
CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.
OTHER HEALTH PROFESSIONALS: Contact your respective board regarding approval.
CE Broker Tracking #50-11357
These courses were recorded January 9-11, 2024 and are valid for credit until January 9, 2027.
DEA Mate Requirement : https://www.deadiversion.usdoj.gov/pubs/docs/MATE_Training_Letter_Final.pdf